Oculis Holding AG (OCS) shares ended the last trading session 8.2% higher at $14.28. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 10.5% gain over the past four weeks. The company is developing OCS-01, a topical eye drop candidate for treating diabetic macular edema and inflammation and pain following cataract surgery, OCS-02 (licaminlimab), a topical biologic anti-TNFα eye drop candidate for dry eye disease and ...

Mr. Char brings extensive experience in leading legal, compliance and corporate governance functions in successful biotech and medical device companies The appointment further expands Oculis' leadership team as the company advances its late-stage pipeline and prepares for commercial phase ZUG, Switzerland, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) ("Oculis"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the appointment of ...

ZUG, Switzerland, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) ("Oculis"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, in collaboration with EURETINA, today announced the winner of the Inaugural Ramin Tadayoni Award. The Ramin Tadayoni Award was established in memory of Oculis' Chief Scientific Officer and a worldrenowned retina specialist in order to pay a lasting tribute to Professor Tadayoni's legacy, who passed away unexpectedly earlie ...

ZUG, Switzerland, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) ("Oculis"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Oculis' management will be attending and presenting at the following upcoming investor conferences: Wells Fargo Healthcare Conference 2024 Event dates: September 4-6, 2024 Location: Encore Boston Harbor, Boston, MA H.C. Wainwright 26th Annual Global Investment Conference Event dates: September 9-11, 202 ...

Exhibit 99.1 Oculis Holding AG Unaudited Condensed Consolidated Interim Financial Statements Table of Contents | Unaudited Condensed Consolidated Interim: | | | --- | --- | | Statements of Financial Position as of June 30, 2024 and December 31, 2023 | 3 | | Statements of Loss for the three and six months ended June 30, 2024 and 2023 | 4 | | Statements of Comprehensive Loss for the three and six months ended June 30, 2024 and 2023 | 5 | | Statements of Changes in Equity for the six months ended June 30, 2024 ...

ZUG, Switzerland, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Following the Company's press release published earlier today, the Q2 Consolidated Financial Statements and the MD&A, which have now been filed with the SEC on form 6-K, are attached. Attachments ...

ZUG, Switzerland, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Reported positive topline results for the Phase 2b RELIEF trial of OCS-02 (licaminlimab) paving the way for potentially the first precision medicine in Dry Eye Disease (DED) Phase 2 ACUITY trial of OCS-05 in acute optic neuritis (AON) is on track for topline readout in Q4 2024 Pre-NDA meeting with U.S. Food and Drug Administration (FDA) completed in August for once daily OCS-01 for the treatment of post-operative inflammation and pain following ocular surg ...

Reported positive topline results for the Phase 2b RELIEF trial of OCS-02 (licaminlimab) paving the way for potentially the first precision medicine in Dry Eye Disease (DED) Phase 2 ACUITY trial of OCS-05 in acute optic neuritis (AON) is on track for topline readout in Q4 2024 Pre-NDA meeting with U.S. Food and Drug Administration (FDA) completed in August for once daily OCS-01 for the treatment of post-operative inflammation and pain following ocular surgery; Providing a clear path forward for NDA submissi ...

Company Overview - Oculis is a global biopharmaceutical company focused on saving sight and improving eye care [3] - The company has a differentiated pipeline with multiple innovative product candidates, including OCS-01 for diabetic macular edema and post-cataract surgery inflammation, licaminlimab (OCS-02) for dry eye disease and non-infectious anterior uveitis, and OCS-05 for acute optic neuritis [3] - Oculis is headquartered in Switzerland and operates in the U.S. and Iceland, aiming to enhance the health and quality of life for patients globally [3] Management and Events - Riad Sherif, M.D., the CEO of Oculis, will participate in a panel discussion on "Derisked Late-stage Candidates for Retinal Disorders" on August 15, 2024 [2] - A virtual company presentation will also be available on-demand on the same date [2] - Oculis management will participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference [4]

ZUG, Switzerland, June 27, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS))) ("Oculis" or the "Company"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, announces, in collaboration with EURETINA, the Ramin Tadayoni Award. "Prof. Ramin Tadayoni was an exceptional friend and a highly accomplished and world-renowned retina specialist that, as an advisor, played a key part in Oculis progress since its inception, and most recently as its Chief Scient ...